Design of targeted intravesical therapies for treating recurrent urinary tract infections

2016年，国家卫生研究所报告称，尿路感染是全球9200多万受影响人口中最常见的感染类型之一。尿路感染是导致死亡的重要原因，特别是在老年人群中，与尿路感染相关的症状占所有初级保健咨询的1-3%，是社区开出13.7%的抗生素处方的主要原因。尿路感染的治疗费用给NHS带来了巨大的负担。目前的抗生素治疗大多是全身性的，这会使整个身体暴露在药物之下。这导致了最近报道的尿路感染病例中6%的耐药性。该项目的目标是开发和评估一种新的基于纳米颗粒的局部治疗方法，这种治疗方法可以直接进入目标器官膀胱。

The National Institute for Health Research in 2016 reported that UTIs are among the most common types of infections within excess of 92 million people affected worldwide. UTIs are a significant cause of mortality, especially amongst the elderly population, with UTI related symptoms accounting for between 1-3% of all primary care consultations and being the main reason for 13.7% of community antibiotic prescriptions. The treatment costs of UTIs place a significant burden on the NHS. The current antibiotic treatments are mostly systemic in nature which exposes the whole body to the drug. This has contributed to the recently reported 6% of drug-resistance in UTI cases. This project will aim to develop and evaluate a new nanoparticle-based localised treatment that can directly administer into the bladder, the target organ.